We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 07, 2020

Everolimus Plus Exemestane in Metastatic HR+ Breast Cancer Previously Treated With CDK4/6 Inhibitors

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Everolimus Plus Exemestane Treatment in Metastatic Hormone Receptor-Positive Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor Therapy
Oncologist 2020 Nov 23;[EPub Ahead of Print], MM Cook, LA Rabadi, AJ Kaempf, MM Saraceni, MA Savin, ZI Mitri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading